19 June 2013
Keywords: uk, nice, says, roche, tarceva, swiss, drug
Article | 19 March 2007
Swiss drug major Roche's lung cancer product Tarceva (erlotinib) has been rejected by the National Institute of Clinical Health and
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
19 March 2007
18 June 2013
© 2013 thepharmaletter.com